Ultragenyx Pharmaceutical (RARE) stock price, revenue, and financials

Ultragenyx Pharmaceutical market cap is $5.5 b, and annual revenue was $271.03 m in FY 2020

$5.5 B

RARE Mkt cap, 14-Oct-2021

$99.4 M

Ultragenyx Pharmaceutical Revenue Q1, 2021
Ultragenyx Pharmaceutical Net income (Q1, 2021)-136.1 M
Ultragenyx Pharmaceutical EBIT (Q1, 2021)-106.6 M
Ultragenyx Pharmaceutical Cash, 31-Mar-2021383.8 M
Get notified regarding key financial metrics and revenue changes at Ultragenyx PharmaceuticalLearn more
Banner background

Ultragenyx Pharmaceutical Income Statement

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

93.0k149.0k17.0k111.0k198.0k10.7m12.8m11.8m18.2m24.1m25.8m36.3m61.7m81.5m99.4m

Cost of goods sold

225.0k141.0k273.0k452.0k766.0k

Gross profit

10.5m12.7m11.5m17.7m23.4m

Gross profit Margin, %

98%99%98%98%97%

R&D expense

8.4m11.2m12.9m17.4m23.1m29.7m40.4m43.3m48.7m51.3m58.4m60.4m75.5m76.8m70.0m78.1m96.0m100.1m113.0m80.7m87.3m147.5m

General and administrative expense

2.0m2.4m3.0m4.1m7.0m10.2m13.2m14.7m17.2m18.7m20.0m23.5m31.4m30.7m31.1m38.8m39.8m41.0m47.5m42.3m42.1m53.3m

Operating expense total

10.3m13.7m15.8m21.5m30.1m39.9m53.6m58.1m65.9m70.0m78.4m83.9m106.9m107.6m101.1m116.9m135.9m141.2m160.5m123.0m129.4m200.8m

EBIT

(10.3m)(13.7m)(15.8m)(21.5m)(30.1m)(39.9m)(53.6m)(58.1m)(65.8m)(70.0m)(78.4m)(83.7m)(96.5m)(94.9m)(89.6m)(99.2m)(112.5m)(118.0m)(120.7m)(63.1m)(50.3m)(106.6m)

EBIT margin, %

(11117%)(9168%)(341488%)(59264%)(42279%)(904%)(742%)(762%)(546%)(466%)(457%)(332%)(102%)(62%)(107%)

Interest expense

14.0k123.0k355.0k704.0k865.0k1.1m876.0k1.7m5.6m4.5m

Interest income

171.0k273.0k456.0k673.0k984.0k971.0k922.0k1.1m1.2m1.1m1.7m2.4m2.7m3.1m4.1m3.3m2.9m1.8m1.3m639.0k

Pre tax profit

(72.9m)(79.2m)30.3m(52.6m)(87.1m)(96.5m)(99.0m)(112.7m)(118.6m)25.7m(68.5m)(135.8m)

Income tax expense

14.0k4.0k39.0k102.0k247.0k216.0k213.0k293.0k409.0k415.0k313.0k379.0k

Net Income

(13.6m)(13.6m)(15.8m)(21.4m)(29.8m)(39.2m)(52.8m)(56.9m)(64.9m)(68.3m)(72.9m)(79.2m)30.3m(52.7m)(87.3m)(96.8m)(99.2m)(113.0m)(119.0m)25.3m(68.8m)(136.1m)

Ultragenyx Pharmaceutical Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

24.3m93.6m161.1m100.5m113.4m433.6m713.5m

Accounts Receivable

5.2m12.7m32.8m23.1m

Prepaid Expenses

28.7m42.9m51.4m57.6m

Inventories

5.9m13.1m20.1m757.0k7.1m11.5m13.0m

Current Assets

193.4m450.2m401.7m269.6m522.4m851.0m1.3b

PP&E

3.0m7.4m17.1m21.8m20.0m44.3m73.5m

Goodwill

44.4m44.4m44.4m44.4m

Total Assets

198.0m559.6m540.6m490.8m719.6m1.1b1.8b

Accounts Payable

4.9m2.9m5.4m8.9m12.3m12.9m12.9m

Current Liabilities

12.5m27.9m60.3m71.0m74.7m103.3m189.6m

Long-term debt

29.8m

Total Debt

29.8m

Total Liabilities

66.7m107.3m110.7m481.7m605.2m

Common Stock

44.0k51.0k58.0k67.0k

Additional Paid-in Capital

324.1m816.6m1.0b1.2b1.6b2.1b2.8b

Retained Earnings

(139.0m)(284.7m)(530.5m)(832.7m)(1.0b)(1.4b)(1.6b)

Total Equity

531.1m474.0m383.5m608.9m653.8m1.2b

Financial Leverage

1.1 x1.1 x1.3 x1.2 x1.7 x1.5 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

55.4m17.5m53.4m178.0m52.4m166.7m70.8m55.1m142.3m159.5m90.8m60.4m226.7m110.9m83.0m269.7m131.3m122.6m298.2m335.6m197.5m383.8m

Accounts Receivable

3.7m17.4m9.2m15.6m20.9m23.1m29.3m14.9m27.8m25.0m

Prepaid Expenses

4.2m4.9m5.5m6.9m9.4m12.3m17.1m17.8m18.9m19.2m19.7m19.4m34.0m36.8m49.7m45.0m46.6m49.2m64.8m58.2m64.3m68.0m

Inventories

2.1m3.3m5.6m10.9m13.6m14.1m11.4m11.1m14.5m12.5m

Current Assets

169.6m158.2m206.7m350.5m336.5m460.7m430.2m411.1m416.8m444.7m419.8m390.9m581.6m604.7m567.5m786.9m699.4m613.5m894.3m906.0m872.0m1.1b

PP&E

1.8m2.5m2.6m3.5m4.8m6.3m13.4m17.1m18.2m16.5m16.4m16.0m20.8m20.9m19.8m21.7m25.3m31.9m47.6m48.3m48.8m87.6m

Goodwill

44.4m44.4m44.4m44.4m44.4m44.4m44.4m44.4m44.4m44.4m

Total Assets

172.7m162.6m210.9m355.8m343.0m602.1m524.2m482.0m515.2m545.8m497.5m435.0m817.4m806.0m765.1m1.0b958.9m879.9m1.2b1.3b1.3b1.6b

Accounts Payable

3.5m3.6m4.2m5.8m10.2m4.4m6.0m7.0m6.6m8.3m11.9m9.3m7.6m10.3m8.2m12.7m8.7m13.5m14.4m9.0m10.9m15.7m

Short-term debt

7.5m7.3m7.8m

Current Liabilities

6.8m8.9m11.1m14.2m23.0m24.7m29.9m32.0m50.4m51.8m62.7m64.3m57.6m66.0m66.7m66.9m75.0m90.3m196.9m219.7m201.2m127.0m

Long-term debt

23.0m33.0m31.2m35.0m36.3m36.7m

Total Debt

23.0m33.0m31.2m42.4m43.6m44.5m

Total Liabilities

7.0m9.5m11.6m14.7m23.7m25.4m34.4m38.1m59.3m57.3m68.1m69.5m93.7m102.1m102.5m121.0m139.1m152.7m624.0m618.5m602.2m543.2m

Common Stock

30.0k30.0k32.0k36.0k36.0k39.0k39.0k39.0k40.0k42.0k42.0k42.0k50.0k50.0k51.0k57.0k58.0k58.0k59.0k60.0k61.0k67.0k

Additional Paid-in Capital

258.6m259.6m321.7m501.6m509.7m806.2m827.1m837.9m915.1m1.1b1.1b1.1b1.5b1.6b1.6b2.0b2.0b2.1b2.2b2.2b2.3b2.8b

Retained Earnings

(92.9m)(106.5m)(122.3m)(160.4m)(190.2m)(229.4m)(337.4m)(394.3m)(459.2m)(598.8m)(671.7m)(750.9m)(802.4m)(855.1m)(942.5m)(1.1b)(1.2b)(1.3b)(1.6b)(1.5b)(1.6b)(1.8b)

Total Equity

165.7m153.1m199.3m341.1m319.3m576.8m489.8m443.9m455.9m488.5m429.5m365.6m723.7m704.0m662.6m886.7m819.8m727.3m609.1m695.6m666.2m1.1b

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0 x

Financial Leverage

1 x1.1 x1.1 x1 x1.1 x1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.2 x1.1 x1.1 x1.2 x1.1 x1.2 x1.2 x2 x1.9 x1.9 x1.5 x

Ultragenyx Pharmaceutical Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(59.8m)(145.6m)(245.9m)(302.1m)(197.6m)(402.7m)(186.6m)

Depreciation and Amortization

684.0k1.4m3.4m5.8m19.5m8.5m12.3m

Accounts Receivable

(7.6m)(20.1m)9.8m

Inventories

(4.1m)(7.1m)(7.1m)(5.3m)(4.5m)(1.3m)

Accounts Payable

3.2m(2.0m)2.5m3.5m3.4m

Cash From Operating Activities

(44.6m)(106.0m)(161.0m)(253.8m)(290.6m)(345.4m)(132.2m)

Purchases of PP&E

(2.1m)(5.0m)(10.2m)(2.8m)(4.1m)(24.8m)(43.9m)

Cash From Investing Activities

(123.4m)(292.4m)89.9m56.4m(33.3m)(13.0m)(179.1m)

Short-term Borrowings

(4.9m)

Cash From Financing Activities

185.0m467.6m138.7m136.3m336.9m679.3m600.3m

Net Change in Cash

(60.6m)12.5m320.7m290.1m

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(13.6m)(27.2m)(43.1m)(21.4m)(51.2m)(90.4m)(52.8m)(109.7m)(174.6m)(68.3m)(141.2m)(220.4m)30.3m(22.5m)(109.8m)(96.8m)(195.9m)(308.9m)(119.0m)(93.7m)(162.6m)(136.1m)

Depreciation and Amortization

117.0k278.0k472.0k201.0k463.0k904.0k544.0k1.2m2.3m1.2m2.2m3.3m6.2m12.2m16.6m2.1m4.2m6.4m2.9m6.0m9.1m3.4m

Accounts Receivable

(9.2m)(2.9m)(8.2m)(10.4m)3.5m18.0m5.1m(2.0m)

Inventories

(3.6m)(6.0m)(6.6m)149.0k521.0k(2.6m)474.0k

Accounts Payable

2.1m2.0m2.7m437.0k4.8m(544.0k)2.6m2.8m3.8m3.0m6.4m3.9m(1.3m)1.4m(593.0k)(151.0k)(3.6m)266.0k

Cash From Operating Activities

(8.3m)(18.9m)(29.9m)(17.7m)(34.9m)(65.5m)(44.9m)(84.5m)(113.3m)(61.2m)(110.0m)(172.0m)(89.5m)(165.6m)(234.7m)(95.8m)(184.8m)(273.3m)(95.2m)(7.8m)(69.8m)(159.3m)

Purchases of PP&E

(569.0k)(1.3m)(1.7m)(459.0k)(1.1m)(3.0m)(1.5m)(6.5m)(9.5m)(485.0k)(861.0k)(1.9m)(475.0k)(1.9m)(2.9m)(3.1m)(8.3m)(13.3m)(14.1m)(18.2m)(22.0m)(16.4m)

Cash From Investing Activities

(65.4m)(92.9m)(106.4m)(4.1m)(115.1m)(258.8m)21.8m45.8m98.3m(9.4m)(30.5m)(688.0k)(71.0m)(123.1m)(106.9m)(101.2m)(159.6m)(80.3m)(95.1m)(181.3m)(277.0m)(182.4m)

Long-term Borrowings

(33.0k)(91.0k)(149.0k)

Dividends Paid

(4.3m)(4.3m)(4.3m)

Cash From Financing Activities

121.8m121.8m182.3m175.4m178.0m466.7m314.0k289.0k63.7m69.0m70.5m71.8m286.4m299.6m324.6m353.6m363.0m363.9m55.6m91.4m110.6m12.6m

Net Change in Cash

48.0m10.0m46.0m153.7m28.0m142.4m(22.8m)(38.5m)48.7m(1.6m)(70.4m)(100.7m)126.2m10.3m(17.6m)156.5m18.5m9.7m(135.3m)(97.8m)(236.0m)(329.9m)

Ultragenyx Pharmaceutical Ratios

USDQ1, 2014

Financial Leverage

1 x

Ultragenyx Pharmaceutical Employee Rating

4.3130 votes
Culture & Values
3.9
Work/Life Balance
3.3
Senior Management
3.2
Salary & Benefits
3.9
Career Opportunities
3.2
Source